Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by lonc17on May 09, 2024 4:58pm
173 Views
Post# 36032178

First Quarter Conference Call

First Quarter Conference CallQuick summary of important points:

1. ONC has 9 months cash as of March 31, 2024. This is a big concern. ONC claims to have sufficient funds to continue with TWO REGISTRATIONS TRIALS. This is false. They do NOT have enough cash to enter into any major trials at this time. 

2. ONC has now admitted that the anticipated Breast Cancer "registrational enabling" trial that is forever being kicked further into the future will now be a trial that is effiecient, flexible and might lead to approval.  But they also said that it could lead to a phase 3. Seriously. Listen to the call. It appears now that the reason they dropped the "Phase 3" and now call it "Registrational Enabling" is because they are hoping and praying for a homerun with a smaller patient set. Clearly, they DO NOT have funds and they DO NOT have a partner lined up for Breast Cancer. 

3.  The most promising news, strangly, is that ONC says the will "provide and update" on the registraional trial for Panc in H1, 2024.  That gives them less than 7 weeks to provide the promised update. They could have done it today, of course, except (and here's the hope) MAYBE they are close to announcing a partnership for this trial and they are within 7 weeks of getting it all signed off and such. Let's hope so, becuase there is NO HOPE for ONC ever getting anywhere near a phase 3 in Breast Cancer. 


<< Previous
Bullboard Posts
Next >>